GlassScriptPhysician profile
James D Sigler
NPI 1043357304
$10,396.16
in general payments reported to CMS, 2019-2025
34 companies · $1,047 in 2025
The $1,047 reported for 2025 was more than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,434 · 2020: $2,851 · 2021: $1,269 · 2022: $522 · 2023: $908 · 2024: $2,364 · 2025: $1,047.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,481 · Travel and Lodging: $1,837.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,481.45 |
| Travel and Lodging | $1,837.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $5,210.05 | 2019-2025 | Proclaim, Eterna, Axium |
| Surgentec | $1,837.34 | 2024 | Ion, Tilink |
| Collegium Pharmaceutical, INC. | $723.77 | 2019-2025 | Belbuca, Xtampza |
| Boston Scientific Corporation | $469.61 | 2019-2025 | Intracept |
| Nalu Medical, INC. | $329.50 | 2021-2025 | Nalu Neurostimulation System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $189.89 | 2019-2023 | Relistor |
| Tersera Therapeutics LLC | $161.65 | 2019-2020 | |
| Vertiflex, INC. | $157.29 | 2019 | |
| Forte Bio-Pharma LLC | $142.03 | 2024-2025 | Prolate, Nalocet, Tanlor |
| Biodelivery Sciences International, INC. | $140.25 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $113.87 | 2023 | Iovera |
| Abbvie INC. | $113.84 | 2022-2024 | Qulipta |
| Stimwave Technologies Incorporated | $100.00 | 2019 | |
| Spr Therapeutics, INC | $97.61 | 2019-2024 | Sprint Pns System |
| Biotronik Nro, INC. | $85.95 | 2025 | Prospera |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $83.11 | 2020 | |
| Painteq LLC | $65.54 | 2023-2024 | Painteq |
| Linvatec Corporation | $45.72 | 2023 | Hall Power |
| Pfizer INC. | $39.21 | 2019-2023 | |
| Lilly USA, LLC | $38.05 | 2020 | |
| Spinal Simplicity, LLC | $26.04 | 2020 | |
| Arbor Pharmaceuticals, INC. | $25.49 | 2020-2021 | |
| Saluda Medical Americas, INC. | $25.24 | 2025 | Evoke |
| Teva Pharmaceuticals USA, INC. | $23.71 | 2019 | |
| Daiichi Sankyo INC. | $19.21 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $17.97 | 2020 | |
| Virtus Pharmaceuticals LLC | $17.66 | 2021 | |
| Mml US, INC. | $16.66 | 2023 | Reactiv8 |
| Ultragenyx Pharmaceutical INC. | $15.79 | 2019 | |
| Curonix LLC | $15.43 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Biohaven Pharmaceutical Holding Company LTD. | $13.10 | 2022 | |
| Zimmer Biomet Holdings, INC. | $12.38 | 2019 | |
| Endo Pharmaceuticals INC. | $12.33 | 2019 | |
| Stryker Corporation | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Sigler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.